经导管的序贯性化疗预防肝癌术后复发  

Sequential Transcatheter Chemotherapy Prevent Recurrence of Postoperational Liver Cancer

作　　者：周载平[1] 胡泽民[2] 余元龙[1] 谢钢[1] 倪恿文[2] 

机构地区：[1]广东省中山市人民医院普外一科,广东中山528403 [2]江西医学院第二附属医院肿瘤科,江西南昌330006

出　　处：《江西医学院学报》2003年第6期80-82,共3页Acta Academiae Medicinae Jiangxi

摘　　要：目的　探讨经肝动脉、门静脉插管的序贯性化疗在预防肝癌术后复发中的价值。方法　 133例肝癌肝切除术中选择 38例进行肝动脉、门静脉插管和或双插管 ,术后序贯性灌注阿霉素等细胞毒性药物 ,评估其对首次复发时间和第 0 .5、1、2年复发率的影响。结果　导管化疗组无瘤生存期为 ( 9.3± 2 .8)个月 (n =38) ,单纯切除组为 ( 6 .8± 3.9)个月 ;导管化疗组术后 0 .5、1、2年复发率为 10 .5 %、2 1.1%、4 7.4 % ,单纯切除组为 12 .6 %、36 .8%、6 5 .3%。结论　经导管的灌注化疗可以较有效地预防肝癌术后的中远期复发。Objective discuss role of sequential perfusion chemotherapy of transhepatic artery and portal vein to prevent recur of postoperational liver cancer.Method during hepatectomy of 133 cases,38 cases were performed transhepatic or/and portal vein intubation,sequentially infused with cell toxical drugs such as adriamycin,etc.then the influence on first recurrent time and recurrent rate of half?1?2 years were assessed.Results free cancer existing time was(9.3±2.8)months in transcatheter group,(.8±3.9)onths in single resection group,postoperational recurrence rate of 1/2?1?2 years was 10.5%?21.1%?47.4% in transcatheter group,12.6%?36.8%?65.3% in single resection group.Conclusions sequential transcatheter infusion chemotherapy can effectively prevent medium term and long term recurrence of postoperational liver cancer.

关 键 词：肝癌 手术后 序贯性化疗 肝动脉 门静脉 复发 

分 类 号：R735.7[医药卫生—肿瘤] R730.53[医药卫生—临床医学]